Irbesartan
- Generic Name
- Irbesartan
- Brand Names
- Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N6O
- CAS Number
- 138402-11-6
- Unique Ingredient Identifier
- J0E2756Z7N
- Background
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.
Irbesartan was granted FDA approval on 30 September 1997.
- Indication
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.
- Associated Conditions
- Diabetic Nephropathy, Hypertension
Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 968
- Registration Number
- NCT00847834
- Locations
- 🇨🇳
Sanofi aventis administrative office, Beijing, China
Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan
- Conditions
- Kidney Failure, Chronic
- Interventions
- Drug: Placebo matching irbesartan 150 mg
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 82
- Registration Number
- NCT00791830
- Locations
- 🇩🇰
Department of Nephrology, Aarhus University Hospital, Skejby, Aarhus N, Denmark
🇩🇰Department of Medicine, Fredericia Hospital, Fredericia, Denmark
🇩🇰Haemodialysis unit, Horsens Hospital, Horsens, Denmark
Role of AT1-receptor Blockers in Insulin-induced Vasodilation.
- Conditions
- HypertensionInsulin ResistanceMicrocirculation
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT00742066
- Locations
- 🇳🇱
University Hospital Maastricht, Maastricht, P.O. Box 5800, Netherlands
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2010-07-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 832
- Registration Number
- NCT00708344
- Locations
- 🇻🇪
Sanofi-Aventis Administrative Office, Caracas, Venezuela
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00660309
- Locations
- 🇺🇸
Novartis Investigator Site, Boston, Massachusetts, United States
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
- Conditions
- IgA Nephropathy
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 151
- Registration Number
- NCT00657059
- Locations
- 🇨🇳
The 1st Affiliated Hospital, Sun Yet-sen University, Guangzhou, Guangdong, China
A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 261
- Registration Number
- NCT00635232
- Locations
- 🇺🇸
MD Medical Research, Oxon Hill, Maryland, United States
🇺🇸East-West Medical Research Institute, Honolulu, Hawaii, United States
🇺🇸Cedar Crosse Research Center, Chicago, Illinois, United States
Irbesartan and Adhesion Molecules in AF
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- University of Magdeburg
- Target Recruit Count
- 60
- Registration Number
- NCT00613496
- Locations
- 🇩🇪
University Hospital Magdeburg; Div. of Cardiology, Magdeburg, Germany
Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2007-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 115
- Registration Number
- NCT00564187
- Locations
- 🇹🇳
Sanofi-Aventis, Megrine, Tunisia
The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2007-11-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1005
- Registration Number
- NCT00562809
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.